Although this class of drugs, called glucagon-like peptide-1 or GLP-1, have been around for more than 17 years, with the first one, Byetta, approved in 2005, it is only recently that the class has made a big name for itself with the introduction of the popular once-weekly diabetic drug, Ozempic , and the equally popular obesity drug, Wegovy (the same drug as Ozempic but with a different dose)
This equates to a missed period and a missed opportunity for conception, if that is your goal

Key Takeaways No clinical trials have studied combining retatrutide and semaglutide: There is zero published human data on co-administration safety or efficacy Overlapping GLP-1 receptor activation creates compounding risk: Both compounds activate GLP-1 receptors, meaning combined use would double-stimulate the same pathway FDA labeling warns against GLP-1 agonist stacking: Approved GLP-1 drugs explicitly advise against co-administration with other GLP-1 receptor agonists Retatrutide already covers all three receptor pathways: As a triple agonist (GLP-1 + GIP + glucagon), adding semaglutide provides no additional receptor coverage Preclinical mouse data showed no added benefit: Combining retatrutide and semaglutide did not produce statistically different gastric emptying effects versus retatrutide alone Retatrutide is not yet FDA-approved: It remains investigational under Eli Lilly's TRIUMPH Phase 3 program with results expected through 2026 Why People Ask About Combining Retatrutide and Semaglutide The question of whether you can take retatrutide and semaglutide together comes up frequently in peptide research communities

This may offer therapeutic applications in injury recovery and post-surgery settings
Patients who took tirzepatide lost more weight than those on semaglutide at every measured interval
This class of medications contains the popular semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon)